Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 6 , Pages 633-642 , November 2009

Cancer chemotherapy in the older cancer patient

  • Ignazio Carreca, M.D.

      Affiliations

    • University of Palermo School of Medicine, Palermo, Italy
    • ,
  • Lodovico Balducci, M.D.

      Affiliations

    • Senior Adult Oncology Program, Moffitt Cancer Center, Tampa, FL 33612, USA
    • Corresponding Author InformationCorresponding author. Tel.: 813-7458658; fax: 813-7451908

References 

  1. Balducci L, Ershler WB. Cancer and aging: A nexus at several levels. Nat Rev Cancer. 2005;5:655–662
  2. Duthie E. Physiology of age: Relevance to symptoms, perceptions, and treatment tolerance. In:  Balducci L,  Lyman GH,  Ershler WB, et al. editor. Comprehensive Geriatric Oncology. London: Taylor and Francis; 2004;p. 207–223
  3. Balducci L. Cancer chemotherapy in the older person. In:  Balducci L,  Ershler B,  DeGaetano G editor. Blood disorders in the elderly. Cambridge: University Press; 2008;p. 225–236
  4. Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults: Toward a better understanding of physiology and etiology (Summary of the proceedings of the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults, Jun 2006). J Am Geriatr Soc. 2006;54:991–1001
  5. Ferrucci L, Corsi A, Lauretani F, et al. The origin of age-related pro-inflammatory state. Blood. 2005;105:2294–2299
  6. Jenny NS, Yanez ND, Psaty BM, et al. Inflammation biomarkers and near-term death in older men. Am J Epidemiol. 2007;165:684–695
  7. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med. 2003;114:180–187
  8. Störk S, Feelders RA, van der Beld AW, et al. Prediction of mortality risk in the elderly. Am J Med. 2006;119:519–525
  9. Carey EC, Covinsky KE, Lui LY, et al. Prediction of mortality in community-living frail elderly people with long-term care needs. J Am Geriatr Soc. 2008;56:68–75
  10. Lee SJ, Lindquist K, Segal MR, et al. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA. 2006;295:801–808
  11. Extermann M, Chen A, Cantor AB, et al. Predictors of tolerance of chemotherapy in older patients. Eur J Cancer. 2002;38:1466–1473
  12. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: Findings from Intergroup Trial 0114. J Clin Oncol. 2004;22:648–657
  13. Balducci L, Ferrucci L. Anemia of aging and cancer. Semin Hematol. 2008;45:243–249
  14. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26:132–149
  15. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9,353 patients. J Natl Cancer Inst. 2006;98:708–714[Review]
  16. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration in the treatment of cancer associated anemia. JAMA. 2008;299:914–924
  17. Aapro M, Leonard RC, Barnadas A, et al. Effect of once-weekly epoetin β on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: Results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol. 2008;26:592–598
  18. Inouye SK, Studenski B, Timetti ME, et al. Geriatric syndromes: Clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007;55:780–791[Review]
  19. Tinetti ME, Gordon C, Sogolow E, et al. Fall-risk evaluation and management: Challenges in adopting geriatric care practices. Gerontologist. 2006;46:717–725
  20. Ethgen O, Gillain D, Gillet P, et al. Age- and sex-stratified prevalence of physical disabilities and handicap in the general population. Aging Clin Exp Res. 2004;16:389–397
  21. Haley WE, Burton AM, Lamonde LA, et al. Family caregiving issues for older cancer patients. In:  Balducci L,  Lyman GH,  Ershler WB, et al. editor. Comprehensive Geriatric Oncology. London: Taylor and Francis; 2004;p. 843–853
  22. Haijar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5:345–351
  23. Rahman A, Pazdur R, Wang Y, et al. The value meal: Effect of food on lapatinib bioavailability. J Clin Oncol. 2007;25:5333–5334
  24. Balducci L, Cohen HJ, Engtrom P, et al. Senior adult oncology clinical practice guidelines in oncology. J Natl Compr Network. 2005;3:572–590
  25. Fried LP, Tangen CM, Wakston J, et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–M156
  26. Anonymous Assessing care of vulnerable elders. 3. Quality indicators. J Am Ger Soc. 2007;55(Suppl 2):464–487
  27. Katz S, Branch LB, Branson MH, et al. Active life expectancy. N Engl J Med. 1983;309:1218–1224
  28. Jagger C, Matthews R, Matthews F, et al. The burden of diseases on disability-free life expectancy in later life. J Gerontol A Biol Sci Med Sci. 2007;62:408–414
  29. Pinder M, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808–3815[Epub 2007 Jul]
  30. Tralongo P, Respini D, Ferrau S. Fatigue and aging. Crit Rev Oncol Hematol. 2003;48(Suppl):57–64
  31. Luciani A, Balducci L, Extermann M, et al. Fatigue may be a cause of functional dependence in older cancer patients. Am J Clin Oncol. 2008;31:424–430
  32. Balducci L, Hardy CL. Hemopoietic reserve and aging. In:  Balducci L,  Ershler WB,  DeGaetano G editor. Blood disorders in the elderly. Cambridge: Cambridge University press; 2008;p. 120–129
  33. Chrischilles EA, Link BK, Scott LD, et al. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate grade non-Hodgkin's lymphoma. Cancer Control. 2003;10:396–403
  34. Balducci L. Cancer chemotherapy in the older person. In:  Balducci L,  Ershler WB,  DeGaetano G editor. Blood disorders in the elderly. Cambridge: Cambridge University Press; 2008;p. 225–236
  35. Schrijvers D, Highley M, DeBruyn E, et al. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs. 1999;10:147–153
  36. Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe, and Wright formulas in estimating renal function in elderly cancer patients. Ann Oncol. 2004;15:291–295
  37. Melchert M, Lancet J. Acute myeloid leukemia in the elderly. In:  Balducci L,  Erhsler WB,  DeGaetano G editor. Blood disorders in the elderly. Cambridge: Cambridge University Press; 2008;p. 237–255
  38. Vitolo U, Ferreri AJ, Montoto S. Follicular lymphomas. Crit Rev Oncol Hematol. 2008;66:248–261
  39. Campisi J. Hot topics aging and cancer. Cell Biol. Aging Cell. 2008;7:281–284
  40. Alekshun TJ, Alsina M. Multiple myeloma. In:  Balducci L,  Erhsler WB,  DeGaetano G editor. Blood disorders in the elderly. Cambridge: Cambridge University Press; 2008;p. 272–289
  41. Daidone MG, Coradini D, Martelli G, et al. Primary breast cancer in elderly women: Biological profile and relation with clinical outcome. Crit Rev Oncol Hematol. 2003;45:313–325
  42. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol. 2007;25:3158–3167
  43. Shayne M, Culakova E, Poniewierski MS, et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer. 2007;110:1611–1620
  44. Smith TJ, Katcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205
  45. Sonis ST. Pathobiology of oral mucositis: Novel insights and opportunities. J Support Oncol. 2007;5(Suppl 4):3–11
  46. Worthington HV, Clarckson JE, Eden OB. Pathobiology of oral mucositis: Novel insights and opportunities. J Support Oncol. 2007;5(Suppl 4):3–11
  47. Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol. 2006;24:5194–5200
  48. Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005;23:7685–7696[Review]
  49. Walker M, Ni O. Neuroprotection during chemotherapy: A systematic review. Am J Clin Oncol. 2007;30:82–92
  50. Schaapveld M, Visser O, Lowman MJ, et al. Risk of new primary non-breast cancers after breast cancer treatment: A Dutch population-based study. J Clin Oncol. 2008;26:1239–1246
  51. Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: The Cancer and Leukemia Group B Experience. J Clin Oncol. 2007;25:3699–3704
  52. Patt DA, Duan Z, Fang S, et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: Understanding risk. J Clin Oncol. 2007;25:3871–3876
  53. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99:196–205
  54. Balducci L, Al Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12:1416–1424
  55. Chlebowski RT. Translating trial data into patients benefits: Making the right choice. Breast. 2008;17(Suppl 3):9–15
  56. Holzberlein JM, Castle EP, Thrasher JB. Complications of androgen-deprivation therapy for prostate cancer. Clin Prostate Cancer. 2003;2:147–152
  57. Balducci L. Molecular insight in cancer treatment and prevention. Int J Biochem Cell Biol. 2007;39:1329–1336
  58. Balducci L, Tam-MacDewitt J, Hauser R, et al. Long overdue: Phase II studies in older cancer patients (Where does the FDA stand?). J Clin Oncol. 2008;26:1387–1388

PII: S1078-1439(09)00258-0

doi: 10.1016/j.urolonc.2009.08.006

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 6 , Pages 633-642 , November 2009

Article Tools

* Image Usage & Resolution